A Phase 1/2 interventional study of Sonrotoclax in Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL) and Relapsed Mantle Cell Lymphoma, sponsored by BeOne Medicines. Active, not recruiting at 65 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by BeOne Medicines · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines — 4 open to participants now, 6 under way, 2 of them phase 3. Lymphoma, Mantle-Cell · BeOne Medicines.
Among the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 1/2, and was the 8th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →4 of the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
BeOne Medicines · Sites in United States, Australia, Brazil and 3 more countries
Ages 18+
BeOne Medicines · Sites in China
Ages 18+
BeOne Medicines · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
By country, each count listing its studies:
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 2
First in 2017; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 136 across the 10 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Lymphoma, Mantle-Cell by BeOne Medicines that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT05294731BeOne MedicinesTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Lymphoma, Mantle-Cell by BeOne Medicines, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study consists of two parts. Part 1 determines the safety and tolerability of sonrotoclax monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of sonrotoclax monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of sonrotoclax monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received sonrotoclax at the target dose of 160 mg orally once a day (QD) after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.
Drug: Sonrotoclax
Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.
Drug: Sonrotoclax
Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with daily dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.
Drug: Sonrotoclax
Participants received sonrotoclax at the target dose of 320 mg orally once a day after an approximately 4-week ramp-up schedule starting at 1 mg with twice-weekly dose increases until the target dose was reached. Participants received sonrotoclax until disease progression, unacceptable toxicity, or consent withdrawal.
Drug: Sonrotoclax
Administered orally
Also known as: BGB-11417
Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
DLTs included the following events without a clear alternative cause other than study drug: Hematologic Toxicity: * Grade ≥ 3 febrile neutropenia; * Grade ≥ 3 thrombocytopenia lasting \> 7 days or resulting in clinically significant bleeding; * Any Grade ≥ 4 hematological toxicities, except for Grade 4 neutropenia lasting ≤ 7 days with or without treatment, Grade 4 lymphopenia, or Grade 4 leukopenia. Nonhematologic Toxicity: • Any Grade ≥ 3 nonhematologic toxicity with the following exceptions: * Laboratory tumor lysis syndrome (TLS) defined by the Howard criteria that resolves (≤ Grade 1 or baseline) in ≤ 3 days; * Individual TLS-related laboratory adverse events that resolve (≤ Grade 1or baseline) in ≤ 3 days with or without treatment; * Grade 3 gastrointestinal toxicity that resolves to ≤ Grade 2 following therapeutic intervention in ≤ 7 days; * Asymptomatic biochemical laboratory abnormalities that resolve (≤ Grade 1 or baseline) in ≤ 7 days with or without supportive care.
Time frame: From first dose in the ramp-up period through the first 3 weeks of treatment at the target dose (approximately 7 weeks)
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.
Time frame: From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.
Part 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events
Tumor lysis syndrome (TLS) occurs when large numbers of cancer cells die rapidly, releasing their contents (such as potassium, phosphorus, and nucleic acids) into the bloodstream faster than the kidneys can filter them out. This rapid breakdown causes a dangerous chain reaction of metabolic and electrolyte imbalances.
Time frame: From first dose of study drug up to 30 days after last dose or the primary analysis data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months.
Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)
ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose
Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State
Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose
Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State
Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose
Time frame: Ramp-up Week 1 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State
Time frame: Target Dose Week 4 Day 1 at predose, 2, 4, 6, and 8 hours post-dose
Part 1: Trough Plasma Concentration (Ctrough) at Steady State
Time frame: Target Dose Week 4 Day 1 at predose
Part 1: Overall Response Rate Assessed by the Independent Review Committee (IRC)
ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Overall Response Rate Assessed by the Investigator
ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per Lugano classification for non-Hodgkin lymphoma.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Duration of Response (DOR) Assessed by the IRC
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause; whichever occurred first, per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. DOR was estimated using the Kaplan-Meier method.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Duration of Response Assessed by the Investigator
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Progression Free Survival (PFS) Assessed by the IRC
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Progression-free Survival Assessed by the Investigator
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Time to Response (TTR) as Assessed by the IRC
Time to response is defined as the time from start of treatment to first documentation of response (PR or better). IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in part 1 was 10.7 (0.1-31.6) months.
Part 1: Time to Response Assessed by the Investigator
TTR is defined as the time from start of treatment to first documentation of response (PR or better).
Time frame: Response was assessed 8 and 16 weeks after the first dose, then every 12 weeks up to one year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 1: Overall Survival (OS)
Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
Time frame: From first dose until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 1 was 10.7 (0.1-31.6) months.
Part 2: Overall Response Rate (ORR) Assessed by the Investigator
ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.
Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Duration of Response Assessed by the IRC
Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Duration of Response Assessed by the Investigator
Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Progression-free Survival Assessed by the IRC
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Progression-free Survival Assessed by the Investigator
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Time to Response Assessed by the IRC
Time to response is defined as the time from start of treatment to first documentation of response (PR or better).
Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Time to Response Assessed by the Investigator
Time to response is defined as the time from start of treatment to first documentation of response (PR or better).
Time frame: Response was assessed at 8 and 16 weeks after the first dose, then every 12 weeks up to 1 year, every 24 weeks for 2 years, and yearly thereafter; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Overall Survival
Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
Time frame: From first dose of study drug until the data cut-off date; median (range) time on follow-up in efficacy-evaluable participants in Part 2 was 14.2 (0.3-24.9) months.
Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Disease Related Symptoms-Physical (DRS-P) Sub-scale Score
The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Disease Related Symptoms - Physical subscale score ranges from 0 to 36, where higher scores indicate better health-related quality of life (HRQoL).
Time frame: Baseline and Weeks 4, 12, and 24
Part 2: Change From Baseline in National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFlymSI-18) Treatment Side-Effects (TSE) Sub-scale Score
The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Treatment Side-Effects subscale score ranges from 0 to 12, where higher scores indicate better health-related quality of life (HRQoL).
Time frame: Baseline and Weeks 4, 12, and 24
Part 2: Change From Baseline in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale (VAS) Score
The EQ-5D VAS measures participants' self-rated health status on a scale from 0 to 100, with 100 = 'the best health you can imagine' and 0 = 'the worst health you can imagine'. Higher scores on VAS indicate higher health status.
Time frame: Baseline and Weeks 4, 12, and 24
Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Treatment Discontinuation
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.
Time frame: From first dose of study drug up to 30 days after last dose or the data cut-off date, whichever occurred earlier; maximum duration of treatment in Part 2 was 24.8 months.
This study is being conducted in 106 sites worldwide. Results are reported up to the primary analysis cut-off date of July 18, 2025.
| Milestone | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) |
|---|---|---|---|---|
| Started | 10 | 12 | 43 | 60 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 10 | 12 | 43 | 60 |
| Withdrew: Death | 7 | 9 | 17 | 21 |
| Withdrew: Remain on study | 3 | 3 | 23 | 34 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 3 |
DLTs included the following events without a clear alternative cause other than study drug: Hematologic Toxicity: * Grade ≥ 3 febrile neutropenia; * Grade ≥ 3 thrombocytopenia lasting \> 7 days or resulting in clinically significant bleeding; * Any Grade ≥ 4 hematological toxicities, except for Grade 4 neutropenia lasting ≤ 7 days with or without treatment, Grade 4 lymphopenia, or Grade 4 leukopenia. Nonhematologic Toxicity: • Any Grade ≥ 3 nonhematologic toxicity with the following exceptions: * Laboratory tumor lysis syndrome (TLS) defined by the Howard criteria that resolves (≤ Grade 1 or baseline) in ≤ 3 days; * Individual TLS-related laboratory adverse events that resolve (≤ Grade 1or baseline) in ≤ 3 days with or without treatment; * Grade 3 gastrointestinal toxicity that resolves to ≤ Grade 2 following therapeutic intervention in ≤ 7 days; * Asymptomatic biochemical laboratory abnormalities that resolve (≤ Grade 1 or baseline) in ≤ 7 days with or without supportive care.
| Participants | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | 0 | 0 |
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.
| Participants | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| TEAEs | 10 | 12 |
| SAEs | 6 | 5 |
| TEAE Leading to Treatment Discontinuation | 2 | 1 |
Tumor lysis syndrome (TLS) occurs when large numbers of cancer cells die rapidly, releasing their contents (such as potassium, phosphorus, and nucleic acids) into the bloodstream faster than the kidneys can filter them out. This rapid breakdown causes a dangerous chain reaction of metabolic and electrolyte imbalances.
| Participants | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Number of Participants Experiencing Tumor Lysis Syndrome (TLS) Adverse Events | 0 | 1 |
ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.
| percentage of participants | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC) | 44.2 (29.1 to 60.1) | 58.3 (44.9 to 70.9) | 52.4 (42.4 to 62.4) |
| h*ng/mL | Part 1: Sonrotoclax Daily Ramp-up |
|---|---|
| Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax After a Single Dose | 8.64 ± 67 |
| h*ng/mL | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Sonrotoclax at Steady-State | 1208.05 ± 27 | 2810.79 ± 72 |
| hours | Part 1: Sonrotoclax Daily Ramp-up |
|---|---|
| Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) After a Single Dose | 4.00 (2.0 to 7.5) |
| hours | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Time to Maximum Observed Concentration of Sonrotoclax (Tmax) at Steady State | 4.12 (3.9 to 6.0) | 4.09 (1.9 to 8.0) |
| ng/mL | Part 1: Sonrotoclax Daily Ramp-up |
|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax After a Single Dose | 1.84 ± 51 |
| ng/mL | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State | 223.84 ± 34 | 559.76 ± 103 |
| ng/mL | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Trough Plasma Concentration (Ctrough) at Steady State | 17.31 ± 134 | 50.49 ± 57 |
ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.
| percentage of participants | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|
| Part 1: Overall Response Rate Assessed by the Independent Review Committee (IRC) | 50.0 (21.1 to 78.9) |
ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) per Lugano classification for non-Hodgkin lymphoma.
| percentage of participants | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Overall Response Rate Assessed by the Investigator | 40.0 (12.2 to 73.8) | 41.7 (15.2 to 72.3) |
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause; whichever occurred first, per the Lugano classification for non-Hodgkin lymphoma. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. DOR was estimated using the Kaplan-Meier method.
| months | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|
| Part 1: Duration of Response (DOR) Assessed by the IRC | 6.0 (0.9 to NA) |
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
| months | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Duration of Response Assessed by the Investigator | NA (7.3 to NA) | 2.8 (2.2 to NA) |
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level. PFS was estimated using the Kaplan-Meier method.
| months | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|
| Part 1: Progression Free Survival (PFS) Assessed by the IRC | 3.8 (1.6 to 22.9) |
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
| months | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Progression-free Survival Assessed by the Investigator | 5.4 (0.5 to NA) | 3.5 (1.6 to 6.5) |
Time to response is defined as the time from start of treatment to first documentation of response (PR or better). IRC review for response assessments was only performed for Part 1 participants assigned to the 320 mg dose level.
| months | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|
| Part 1: Time to Response (TTR) as Assessed by the IRC | 1.81 (1.7 to 2.1) |
TTR is defined as the time from start of treatment to first documentation of response (PR or better).
| months | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Time to Response Assessed by the Investigator | 1.89 (1.4 to 3.6) | 3.55 (1.7 to 6.5) |
Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
| months | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) |
|---|---|---|
| Part 1: Overall Survival (OS) | 11.4 (0.7 to NA) | 9.5 (0.7 to NA) |
ORR is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per the Lugano Classification for non-Hodgin lymphoma.
| percentage of participants | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Overall Response Rate (ORR) Assessed by the Investigator | 41.9 (27.0 to 57.9) | 51.7 (38.4 to 64.8) | 47.6 (37.6 to 57.6) |
Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Duration of Response Assessed by the IRC | 15.8 (4.7 to NA) | 12.4 (7.2 to NA) | 15.8 (7.4 to NA) |
Duration of response is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurred first. DOR was estimated using the Kaplan-Meier method.
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Duration of Response Assessed by the Investigator | 17.2 (7.4 to NA) | 13.1 (6.7 to NA) | 15.8 (8.4 to NA) |
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Progression-free Survival Assessed by the IRC | 6.3 (1.7 to 9.1) | 9.1 (4.0 to NA) | 6.5 (4.0 to 10.4) |
PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method.
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Progression-free Survival Assessed by the Investigator | 3.7 (1.7 to 9.1) | 8.6 (4.3 to 12.0) | 6.4 (3.7 to 9.1) |
Time to response is defined as the time from start of treatment to first documentation of response (PR or better).
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Time to Response Assessed by the IRC | 1.87 (1.7 to 4.6) | 1.94 (1.6 to 6.2) | 1.91 (1.6 to 6.2) |
Time to response is defined as the time from start of treatment to first documentation of response (PR or better).
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Time to Response Assessed by the Investigator | 1.89 (1.7 to 3.9) | 1.94 (1.6 to 4.0) | 1.91 (1.6 to 4.0) |
Overall survival is defined as the time from the start of treatment to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
| months | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Part 2: Overall Survival | NA (7.3 to NA) | NA (14.8 to NA) | NA (14.8 to NA) |
The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Disease Related Symptoms - Physical subscale score ranges from 0 to 36, where higher scores indicate better health-related quality of life (HRQoL).
| score on a scale | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Week 4 | 2.1 (0.3 to 3.8) | 0.9 (-0.3 to 2.1) | 1.4 (0.4 to 2.4) |
| Week 12 | 1.4 (-0.4 to 3.2) | 2.3 (1.0 to 3.5) | 1.9 (0.9 to 3.0) |
| Week 24 | 1.2 (-0.7 to 3.1) | 1.2 (-0.2 to 2.5) | 1.2 (0.1 to 2.3) |
The NFlymSI-18 is a patient-reported outcome questionnaire that was developed to measure disease-specific symptoms and/or treatment-related concerns in patients with advanced lymphoma. The NFLymSI-18 questionnaire includes 18 separate questions about disease symptoms in the last 7 days; participants are asked to respond to each question on a scale from 0 (Not at all) to 4 (Very much). The 18 questions are grouped into 4 subscale scores: "Disease related symptoms - physical," "Disease related symptoms - emotional," "Treatment side effects," and "Function and wellbeing." The Treatment Side-Effects subscale score ranges from 0 to 12, where higher scores indicate better health-related quality of life (HRQoL).
| score on a scale | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Week 4 | 0.5 (-0.2 to 1.2) | 0.4 (-0.2 to 0.9) | 0.4 (-0.0 to 0.9) |
| Week 12 | 0.6 (-0.2 to 1.4) | 1.0 (0.4 to 1.6) | 0.8 (0.4 to 1.3) |
| Week 24 | 0.2 (-0.6 to 1.0) | 0.9 (0.3 to 1.5) | 0.6 (0.1 to 1.1) |
The EQ-5D VAS measures participants' self-rated health status on a scale from 0 to 100, with 100 = 'the best health you can imagine' and 0 = 'the worst health you can imagine'. Higher scores on VAS indicate higher health status.
| score on a scale | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| Week 4 | 8.5 ± 12.19 | 1.0 ± 13.36 | 3.9 ± 13.33 |
| Week 12 | 7.7 ± 11.05 | 4.4 ± 15.14 | 5.7 ± 13.67 |
| Week 24 | 10.0 ± 14.68 | 4.3 ± 20.08 | 6.5 ± 18.22 |
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical adverse event by the investigator or sponsor based on medical judgment.
| Participants | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Part 2: Sonrotoclax 320 mg Total |
|---|---|---|---|
| TEAEs | 43 | 56 | 99 |
| SAEs | 14 | 24 | 38 |
| TEAE Leading to Treatment Discontinuation | 5 | 10 | 15 |
Collected over From first dose of study drug up to 30 days after last dose or the data cut-off date, whichever occurred earlier; maximum duration of treatment was 31 months in Part 1 and 24.8 months in Part 2.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | 7/10 (70%) | 6/10 (60%) | 10/10 (100%) |
| Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | 9/12 (75%) | 5/12 (41.7%) | 12/12 (100%) |
| Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | 17/43 (39.5%) | 14/43 (32.6%) | 42/43 (97.7%) |
| Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | 21/60 (35%) | 24/60 (40%) | 51/60 (85%) |
| Event | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/10 | 0/12 | 0/43 | 1/60 |
| DeathGeneral disorders and administration site conditions | 1/10 | 0/12 | 0/43 | 1/60 |
| COVID-19 pneumoniaInfections and infestations | 1/10 | 0/12 | 0/43 | 1/60 |
| PneumoniaInfections and infestations | 1/10 | 1/12 | 3/43 | 6/60 |
| Respiratory tract infectionInfections and infestations | 1/10 | 0/12 | 0/43 | 0/60 |
| Platelet count decreasedInvestigations | 1/10 | 1/12 | 1/43 | 1/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/10 | 0/12 | 0/43 | 0/60 |
| Cardiac failure congestiveCardiac disorders | 0/10 | 1/12 | 0/43 | 1/60 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 1/12 | 0/43 | 0/60 |
| AppendicitisInfections and infestations | 0/10 | 1/12 | 0/43 | 0/60 |
| Event | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) |
|---|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 8/10 | 5/12 | 11/43 | 4/60 |
| White blood cell count decreasedInvestigations | 7/10 | 4/12 | 11/43 | 10/60 |
| Neutrophil count decreasedInvestigations | 6/10 | 5/12 | 14/43 | 9/60 |
| AnaemiaBlood and lymphatic system disorders | 5/10 | 4/12 | 10/43 | 12/60 |
| Platelet count decreasedInvestigations | 5/10 | 1/12 | 5/43 | 5/60 |
| Aspartate aminotransferase increasedInvestigations | 1/10 | 4/12 | 3/43 | 7/60 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/10 | 4/12 | 1/43 | 2/60 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/10 | 4/12 | 5/43 | 1/60 |
| ConstipationGastrointestinal disorders | 3/10 | 1/12 | 3/43 | 8/60 |
| Lymphocyte count decreasedInvestigations | 3/10 | 1/12 | 4/43 | 1/60 |
| Age, Categorical(Participants) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 3 | 19 | 19 | 46 |
| >=65 years | 5 | 9 | 24 | 41 | 79 |
| Age, Continuous(years) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| Median | 64.0 (43 to 74) | 70.5 (52 to 76) | 66.0 (43 to 85) | 69.0 (39 to 85) | 68.0 (39 to 85) |
| Sex: Female, Male(Participants) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 10 | 17 | 31 |
| Male | 7 | 11 | 33 | 43 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 7 | 18 | 25 |
| Not Hispanic or Latino | 10 | 12 | 34 | 41 | 97 |
| Unknown or Not Reported | 0 | 0 | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| Asian | 10 | 11 | 21 | 13 | 55 |
| White | 0 | 1 | 18 | 42 | 61 |
| Black or African American | 0 | 0 | 1 | 2 | 3 |
| Other | 0 | 0 | 2 | 2 | 4 |
| Not Reported | 0 | 0 | 1 | 1 | 2 |
| Eastern Cooperative Oncology Group Performance (ECOG) Performance Status(Participants) | Part 1: Sonrotoclax 160 mg (Daily Ramp-up) | Part 1: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Daily Ramp-up) | Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) | Total |
|---|---|---|---|---|---|
| 0 (Fully active) | 2 | 4 | 16 | 14 | 36 |
| 1 (Restricted but ambulatory) | 7 | 8 | 27 | 39 | 81 |
| 2 (Ambulatory but unable to work) | 1 | 0 | 0 | 7 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
Ran from Sep 2022 to primary completion in Jul 2025, 34 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 77 phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 114. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonrotoclax